Claims for Patent: 11,273,171

Summary for Patent: 11,273,171

Title:	Methods for treating or preventing ophthalmological conditions
Abstract:	The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.
Inventor(s):	Samir Patel, Richard Everett, Douglas Brooks, Shane Xinxin Tian
Assignee:	Astellas US LLC
Application Number:	US17/346,556
Patent Claims:	1. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly. 2. The method according to claim 1, wherein the pegylated aptamer is provided as a pegylated moiety conjugated to the aptamer via a linker. 3. The method according to claim 2, wherein the pegylated moiety is conjugated to the 5′ end of the aptamer. 4. The method according to claim 2, wherein the pegylated moiety is a branched PEG. 5. The method according to claim 2, wherein the pegylated moiety has a molecular weight greater than about 10 kDA. 6. The method according to claim 2, wherein the pegylated moiety has a molecular weight of about 40 kDa. 7. The method according to claim 1, wherein the pegylated moiety has the following structure: 8. The method according to claim 1, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 10%, as compared to a subject who is not administered the anti-C5 agent. 9. The method according to claim 1, wherein the anti-C5 agent is administered monthly. 10. The method according to claim 9, wherein the anti-C5 agent is administered monthly for three injections, and the fourth and fifth injections are administered three or four months after the third injection. 11. The method according to claim 1, wherein the anti-C5 agent is administered bimonthly. 12. The method according to claim 1, wherein the anti-C5 agent is administered quarterly. 13. The method according to claim 1, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 20% as compared to a subject who is not administered the anti-C5 agent. 14. The method according to claim 1, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 30% as compared to a subject who is not administered the anti-C5 agent. 15. The method according to claim 1, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 40% as compared to a subject who is not administered the anti-C5 agent. 16. The method according to claim 1, wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 50% as compared to a subject who is not administered the anti-C5 agent. 17. The method according to claim 1, wherein growth of the lesion is assessed using autofluorescence imaging or optical coherence tomography. 18. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly, wherein the pegylated moiety is a branched PEG and has a molecular weight greater than about 10 kDA, and wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 30% as compared to a subject who is not administered the anti-C5 agent. 19. A method of treating geographic atrophy in a human subject in need thereof, the method comprising administering via intravitreal injection to said subject about 2 mg/eye of a pegylated aptamer in an amount sufficient to reduce growth of a lesion associated with geographic atrophy in the subject, wherein the aptamer comprises the sequence fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGf UfCfUmGmAmGfUfUfUAfCfCfUmGfCmG-3T (SEQ ID NO:26), wherein fC and fU=2′ fluoro nucleotides, mG and mA=2′-OMe nucleotides, all other nucleotides are 2′-OH, and 3T indicates an inverted deoxythymidine, or a salt thereof, and wherein the pegylated aptamer is administered to the subject biweekly, monthly, or quarterly, wherein the pegylated moiety is a branched PEG and has a molecular weight greater than about 10 kDA, and wherein the growth of the GA lesion in the subject in need thereof is reduced by at least 40% as compared to a subject who is not administered the anti-C5 agent.